VRN110755

VRN110755 is a small-molecule drug developed by Voronoi. Its target is EGFR (the sponsor names EGFR). The sponsor states: A highly selective oral EGFR inhibitor designed to target activating EGFR mutations and selected resistance mutations, including C797S, in EGFR-mutant NSCLC. ClinicalTrials.gov describes the intervention as: VRN110755 is an investigational highly selective oral EGFR inhibitor supplied as capsules for oral administration. The drug is designed to target activating EGFR mutations and selected resistance mutations, including C797S, in patients with. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07699328, plans to enrol 315 participants with primary completion expected 2029-01-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.